Austin Health

Title
Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention.
Publication Date
2022-11-28
Author(s)
Koshy, Anoop N
Giustino, Gennaro
Sartori, Samantha
Kyaw, Htoo
Yadav, Mayank
Zhang, Zhongjie
Hooda, Amit
Farooq, Ali
Krishnamoorthy, Parasuram
Sweeny, Joseph M
Khera, Sahil
Serrao, Gregory W
Sharma, Raman
Suleman, Javed
Dangas, George
Kini, Annapoorna S
Mehran, Roxana
Sharma, Samin K
Subject
acute coronary syndrome
antiplatelet therapy
chronic coronary syndrome
major adverse cardiovascular event(s)
percutaneous coronary intervention
stable ischemic heart disease
Type of document
Journal Article
OrcId
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
DOI
10.1016/j.jcin.2022.09.021
Abstract
Potent P2Y12 agents such as ticagrelor and prasugrel are increasingly utilized across the clinical spectrum of patients undergoing percutaneous coronary intervention (PCI). There is a paucity of data supporting their use in a patient population inclusive of both acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) patients.
Link
link
Citation
JACC. Cardiovascular Interventions 2022; 15(22)
Jornal Title
JACC. Cardiovascular Interventions
ISSN
1876-7605

Files:

NameSizeformatDescriptionLink